Orsted Is Symptomatic of What's Ailing Wind Power
Now, investors are once again disappointed in Orsted, sending its stock plummeting to below its initial public offering price. On Monday, the Danish energy giant announced plans to raise as much as 60 billion Danish kroner ($9.4 billion) via a rights issue — more than half of its market capitalization.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
Novo Nordisk A/S (NYSE:NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Underperform with a $54 price target. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors that it sees a more balanced risk/reward now that the company's 'reality' is better reflected in the shares. Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
38 minutes ago
- Yahoo
Tien Wah Press Holdings Berhad Second Quarter 2025 Earnings: EPS: RM0.011 (vs RM0.013 in 2Q 2024)
Explore Tien Wah Press Holdings Berhad's Fair Values from the Community and select yours Tien Wah Press Holdings Berhad (KLSE:TIENWAH) Second Quarter 2025 Results Key Financial Results Revenue: RM74.5m (down 7.5% from 2Q 2024). Net income: RM1.64m (down 13% from 2Q 2024). Profit margin: 2.2% (down from 2.3% in 2Q 2024). EPS: RM0.011 (down from RM0.013 in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Tien Wah Press Holdings Berhad shares are up 3.1% from a week ago. Risk Analysis Be aware that Tien Wah Press Holdings Berhad is showing 4 warning signs in our investment analysis that you should know about... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Marjorie Taylor Greene Keeps Buying UnitedHealth Stock Along With Fellow Investors Buffett And Burry
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Shares of UnitedHealth Group (NYSE:UNH) soared on Friday with news that several prominent investors had purchased shares of the health insurance company. A well-known member of Congress is also buying up shares and adding to her position. Marjorie Taylor Greene Scoops Up More Shares Rep. Marjorie Taylor Greene (R-Ga.) bought more UnitedHealth stock, according to new filings reported on the Benzinga Government Trades page. In a new filing, Greene revealed four new investments made on Aug. 4, which are listed below: Bought $1,000 to $15,000 in AbbVie Inc (NYSE:ABBV) stock Bought $1,000 to $15,000 in United Parcel Service (NYSE:UPS) stock Bought $1,000 to $15,000 in UnitedHealth stock Bought $50,000 to $100,000 in US Treasury Bills The latest purchase follows several other investments in UnitedHealth stock by Greene in 2025. The Congresswoman also disclosed buying shares in May. On May 14, Greene purchased $15,000 to $50,000 worth of shares. On May 16, Greene purchased shares worth between $1,000 and $15,000. Trending: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — With a current share price of $307.83 at the time of writing and a share range of $236.95 to $242.25 on Aug. 4, the Congresswoman is up at least 27.1% from that trade made less than two weeks ago. The other two trades this year have not performed as well. Here are the price ranges from the two May dates and return for Greene based on the highest price of the stock that day: May 14: $307.11 to $322.94, -4.&% May 16: $269.14 to $294.49, +4.5% The Congresswoman could have had better returns depending on the price paid. UnitedHealth stock fell sharply around the time of the May 16 purchase, with the company announcing CEO Andrew Witty was stepping down and that they were withdrawing guidance. Why It's Important The latest disclosure from Greene follows filings from prominent investors, such as Warren Buffett and Michael Burry, which revealed long positions in the health insurance company. Buffett revealed a stake of more than five million shares in filings from Berkshire Hathaway Inc (NYSE:BRK) (NYSE:BRK). Big Short investor Burry, who leads Scion Asset Management, revealed a long position in UnitedHealth via shares and call options. Citron Research also revealed Friday that Andrew Left was long UnitedHealth stock. Burry and Left are best known for short positions against stocks, making their long stakes in the future success of UnitedHealth particularly interesting to investors. Greene is also not the only member of Congress buying UnitedHealth shares. With investigations into the company, members of Congress may face a conflict of interest if they are required to decide against the health insurance Congressional Trades While Greene doesn't have the same trading record as Buffett and Burry, she has become one of the most followed members of Congress when it comes to stock trading. The Congresswoman's purchases of Palantir stock this year have performed well, but they also raise potential conflicts of interest on the House Committee on Homeland Security. In 2024, Greene's return of +30.2% ranked 23rd among members of Congress according to an annual report from UnusualWhales tracking performance. A bill to ban members of Congress from trading has gained momentum and could change the future of trading for Greene and other members. Greene previously brushed off criticism on the timing of her trades this year, saying she has a portfolio manager who handles her stock transactions. The Congresswoman praised her portfolio manager's timing of buying the dip earlier this year. Benzinga recently polled readers to gauge their stance on a potential ban on Congress members stock trading. 'Should members of Congress be allowed to buy and sell stocks, options and ETFs?' Benzinga asked. These were the results: They should not be allowed to trade stocks, options or ETFs: 43% They should be allowed to trade as long as they report within 24 hours: 24% They should only be allowed to trade ETFs and mutual funds: 14% They should be allowed to trade as long as they report in 45 days: 11% They should only be allowed to trade stocks: 8% The poll found that 43% of readers support an outright ban on members of Congress trading stocks, options, or ETFs. Eleven percent voted that the current rules should be left alone, with a 45-day disclosure window. Read Next: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo: Shutterstock This article Marjorie Taylor Greene Keeps Buying UnitedHealth Stock Along With Fellow Investors Buffett And Burry originally appeared on Sign in to access your portfolio
